Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia

P. J. Hengeveld; J. Schilperoord-Vermeulen; M. Y. van der Klift; J. M. N. Dubois; P. M. Kolijn; F. G. Kavelaars; M. Rijken; J. A. Dobber; K. Nasserinejad; S. Kersting; P. E. Westerweel; A. P. Kater; A. W. Langerak; M. D. Levin

doi:https://doi.org/10.1038/s41408-023-00870-2

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia

P. J. Hengeveld, J. Schilperoord-Vermeulen, M. Y. van der Klift, J. M. N. Dubois, P. M. Kolijn, F. G. Kavelaars, M. Rijken, J. A. Dobber, K. Nasserinejad, S. Kersting, P. E. Westerweel, A. P. Kater, A. W. Langerak, M. D. Levin

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Original language	English
Article number	102
Journal	Blood Cancer Journal
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41408-023-00870-2
Publication status	Published - 1 Dec 2023

Access to Document

https://doi.org/10.1038/s41408-023-00870-2

Cite this

Hengeveld, P. J., Schilperoord-Vermeulen, J., van der Klift, M. Y., Dubois, J. M. N., Kolijn, P. M., Kavelaars, F. G., Rijken, M., Dobber, J. A., Nasserinejad, K., Kersting, S., Westerweel, P. E., Kater, A. P., Langerak, A. W., & Levin, M. D. (2023). Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia. Blood Cancer Journal, 13(1), Article 102. https://doi.org/10.1038/s41408-023-00870-2

@article{1443fec9d59e46d4bea1d398bd15135a,

title = "Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia",

author = "Hengeveld, {P. J.} and J. Schilperoord-Vermeulen and {van der Klift}, {M. Y.} and Dubois, {J. M. N.} and Kolijn, {P. M.} and Kavelaars, {F. G.} and M. Rijken and Dobber, {J. A.} and K. Nasserinejad and S. Kersting and Westerweel, {P. E.} and Kater, {A. P.} and Langerak, {A. W.} and Levin, {M. D.}",

note = "Funding Information: The authors would like to thank all patients, their families, study monitors and investigators that participated in the HOVON-139/GIVE trial. The HOVON-139/GIVE trial was funded by F Hoffmann-La Roche (ML29995), who had the opportunity to review and comment on this paper.",

year = "2023",

month = dec,

day = "1",

doi = "https://doi.org/10.1038/s41408-023-00870-2",

language = "English",

volume = "13",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "1",

}

Hengeveld, PJ, Schilperoord-Vermeulen, J, van der Klift, MY, Dubois, JMN, Kolijn, PM, Kavelaars, FG, Rijken, M, Dobber, JA, Nasserinejad, K, Kersting, S, Westerweel, PE, Kater, AP, Langerak, AW & Levin, MD 2023, 'Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia', Blood Cancer Journal, vol. 13, no. 1, 102. https://doi.org/10.1038/s41408-023-00870-2

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia. / Hengeveld, P. J.; Schilperoord-Vermeulen, J.; van der Klift, M. Y. et al.
In: Blood Cancer Journal, Vol. 13, No. 1, 102, 01.12.2023.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia

AU - Hengeveld, P. J.

AU - Schilperoord-Vermeulen, J.

AU - van der Klift, M. Y.

AU - Dubois, J. M. N.

AU - Kolijn, P. M.

AU - Kavelaars, F. G.

AU - Rijken, M.

AU - Dobber, J. A.

AU - Nasserinejad, K.

AU - Kersting, S.

AU - Westerweel, P. E.

AU - Kater, A. P.

AU - Langerak, A. W.

AU - Levin, M. D.

N1 - Funding Information: The authors would like to thank all patients, their families, study monitors and investigators that participated in the HOVON-139/GIVE trial. The HOVON-139/GIVE trial was funded by F Hoffmann-La Roche (ML29995), who had the opportunity to review and comment on this paper.

PY - 2023/12/1

Y1 - 2023/12/1

UR - http://www.scopus.com/inward/record.url?scp=85163854228&partnerID=8YFLogxK

U2 - https://doi.org/10.1038/s41408-023-00870-2

DO - https://doi.org/10.1038/s41408-023-00870-2

M3 - Comment/Letter to the editor

C2 - 37400508

SN - 2044-5385

VL - 13

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 1

M1 - 102

ER -

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia

Access to Document

Other files and links

Cite this